SCHEMBL377936

SCHEMBL377936

CC(=O)N1CCN(c2ccc(C=O)cc2)CC1C

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
TRIM24 O15164 1/20 0.46
TRIM33 Q9UPN9 1/20 0.46
KDM4E B2RXH2 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SYK P43405 1/20 0.44
BRD4 O60885 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
JAK3 P52333 1/20 0.41
BTK Q06187 1/20 0.41
FAAH O00519 6/20 0.40
SUV39H2 Q9H5I1 1/20 0.39
GRM1 Q13255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17324966 0.82 FAAH (0.53) ALDH1A1KDM4ESMN1; SMN2SYKBRD4
SCHEMBL14320597 0.82 GFER (0.58) ALDH1A1KDM4ESMN1; SMN2SYKBRD4
SCHEMBL26870516 0.82 FAAH (0.53) SMN1; SMN2SYKBRD4SMARCA2SMARCA4
SCHEMBL17324998 0.82 FAAH (0.53) SMN1; SMN2SYKBRD4SMARCA2SMARCA4
SCHEMBL377947 0.81 ALDH1A1 (0.46) ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2
SCHEMBL23544879 0.80 MAPT (0.49) ALDH1A1KDM4ESMN1; SMN2SYKBRD4
SCHEMBL25839431 0.80 MAPT (0.46) ALDH1A1KDM4ESMN1; SMN2SYKBRD4
SCHEMBL23544890 0.80 MAPT (0.46) ALDH1A1KDM4ESMN1; SMN2SYKBRD4
SCHEMBL15533491 0.76 BRD4 (0.51) BRD4SMARCA2SMARCA4PBRM1GRM1
SCHEMBL377648 0.75 GFER (0.65) ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 US disclosed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 US disclosed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 US disclosed
US-9238640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2016-01-19 US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 ALDH1A1 587/4885TRIM24 2111/4885TRIM33 3495/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 ALDH1A1 650/4885TRIM24 2158/4885TRIM33 3360/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 ALDH1A1 3920/4885TRIM24 880/4885TRIM33 879/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 ALDH1A1 587/4885TRIM24 2111/4885TRIM33 3495/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 ALDH1A1 587/4885TRIM24 2111/4885TRIM33 3495/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 ALDH1A1 587/4885TRIM24 2111/4885TRIM33 3495/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 ALDH1A1 650/4885TRIM24 2158/4885TRIM33 3360/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 ALDH1A1 650/4885TRIM24 2158/4885TRIM33 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.